Skip to main content
. 2021 Apr;12(Suppl 1):S59–S67. doi: 10.21037/jgo-20-284

Table 1. Selection criteria for CRS-HIPEC in PM of gastric origin.

Complete cytoreduction possible (CC0)
Low tumor burden (PCI <6)
Locoregional PM (P1)
No small bowel involvement
Synchronous PM
Well-moderately differentiated tumors
No signet ring cell type
Good performance status (ECOG 0)
Prior response to systemic chemotherapy

CRS-HIPEC, cytoreductive surgery-hyperthermic intraperitoneal chemotherapy; PM, peritoneal metastases; PCI, Peritoneal Cancer Index.